BacthQC use cases

Phage genome quality control (QC) is the genomic part of ensuring that produced phages meet their quality requirements. Modern genomic QC uses DNA sequencing to confirm the phage genome matches its original reference genome and the sample is free of contaminating or unwanted sequences. The extent of the analysis may vary, but usually includes identity checks (ensuring the phage is the correct phage to begin with), genome coverage, sequence variants, structural integrity and contamination analysis. Genomic quality control is one pillar of a broader quality control scheme that also involves phenotypic and functional testing, such as titre, potency, host range, lytic activity, purity, endotoxin and sterility tests. Together these confirm what the phage is genetically and how it behaves, ensuring that the phage product meets pre-determined pharmaceutical requirements.

You verify phage genome integrity between production batches by sequencing each batch and comparing it to the characterised reference genome. Read mapping and variant calling detect point mutations, while coverage and softclipping analysis flag larger deletions, insertions, and other structural rearrangements. Contamination is assessed from the fraction of reads mapping to the production host or other control genomes or databases. A batch passes when its genome matches the reference within defined quality thresholds, showing the phage has not changed during production.

Whole-genome sequencing (WGS) using next-generation sequencing (NGS) gives base-level resolution of a phage genome, which underpins GMP phage quality control. During production, WGS is used to confirm genetic stability, coverage, and purity of each batch against the reference genome. Applied within a validated, auditable workflow with defined thresholds, WGS and NGS help manufacturers meet emerging standards.

A genomic Certificate of Analysis (CoA) document records the phage’s identity against an approved reference genome, the lot it belongs to within the project's tiered hierarchy, the sequencing technology and analysis parameters used, and a signed disposition from a genomic perspective. All analysis results are included in the report, including genome coverage and depth, variant count and frequency, structural integrity such as deletions or insertions, ambiguous mappings, and contamination. Variants are listed per position with their type, frequency, and predicted impact. The CoA includes the results of applying a pre-determined set of QC gates called Rulesets. Each quality check is reproduced with its configured threshold, the measured value, and a pass or fail result. Whether the lot is approved or rejected, a certificate is issued, and a rejection also records its reason. In BatchQC, traceability is what makes the CoA a controlled record: different sections of the analysis carry their own electronic signatures under 21 CFR Part 11, and every action is written to an audit trail. Before a certificate can be generated, an automated check confirms that each signature has a recorded signer role. The exact software versions are recorded, including per-step versions for the analysis run, the ruleset application, and the certificate generation, so every result ties back to the precise software versions and configurations.

In GMP/GxP environments, software validation is handled through computerised system validation (CSV), following the GAMP 5 framework. Validation effort is scaled to risk (how much the system could affect patient safety, product quality, and data integrity) and documented across a lifecycle from user requirements through design, risk assessment, and testing to a validation report. Controls for electronic records and signatures (21 CFR Part 11, EU Annex 11) and data integrity (ALCOA+) are central. The manufacturer owns validation, but the vendor supplies supporting documentation through an extensive package that supports expected IQ/OQ/PQ activities.

Phage quality control sits within an evolving regulatory framework rather than a single approval pathway. In Europe, European Pharmacopoeia is setting the first harmonised quality criteria, and the EMA is drafting a human-use quality guideline. Both expect genome characterisation and genetic stability monitoring. In the US, the FDA regulates phages as biologics through the IND route, applying requirements case by case. When producing phages at the GMP-level, QC software must also meet GMP/GxP expectations.

Whether to build or buy a phage genome QC pipeline depends on existing bioinformatic expertise as well as reproducibility, compliance, and maintenance requirements. In-house pipelines using open-source tools are flexible but must be validated, version-controlled, documented, and kept current, which is a significant ongoing effort in a GMP/GxP setting. Maintaining these pipelines usually requires a cross-functional team of bioinformaticians, regulatory experts, developers and IT infrastructure experts. Furthermore, the documentation produced by the QC pipelines can be complex and requires collaboration of internal approvers through external digital-signature services. A dedicated phage QC platform provides standardised rules, defined thresholds, audit trails, and electronic signatures out of the box, and supplies validation documentation, reducing the compliance workload while keeping results reproducible and release-ready.

Yes, phages can mutate during production because they are replicating organisms, and each round of replication in a host can introduce mutations or the incorporation of foreign DNA. Large population sizes combined with short generation times contribute to a diverse pool of phages, where some level of genetic variance is invariably present. If a specific variant is subjected to positive selection during production, a heterogenous population may arise that no longer adheres to your clonal starting point. While the odds of incorporation of antibiotic resistance genes are small, especially if your production host is carefully vetted and production culture is not dependent on antibiotic selection, even tiny mutations may have significant effects on host range and overall effectiveness of the phage. Sequencing each batch against the reference genome detects these changes before release and ensures your product is what you claim it to be.